cytosine has been researched along with B Virus Infection in 51 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the antiviral agent (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (cidofovir) on the EBV-associated tumor nasopharyngeal carcinoma (NPC) was evaluated in NPC xenografts in athymic mice." | 7.70 | The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. ( De Clercq, E; Neyts, J; Pagano, JS; Raab-Traub, N; Sadler, R, 1998) |
| "The effect of the antiviral agent (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (cidofovir) on the EBV-associated tumor nasopharyngeal carcinoma (NPC) was evaluated in NPC xenografts in athymic mice." | 3.70 | The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. ( De Clercq, E; Neyts, J; Pagano, JS; Raab-Traub, N; Sadler, R, 1998) |
| " The frequency and severity of adverse effects, particularly nephrotoxicity, in pediatric HSCT recipients are unclear, and pharmacokinetics (PK) of cidofovir in children have not previously been reported." | 2.80 | Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. ( Braverman, RS; Caruso Brown, AE; Cohen, MN; Giller, R; Levin, MJ; Rooney, JF; Tong, S, 2015) |
| "Foscarnet has also been shown to be effective as preemptive therapy for CMV in allogenic stem cell transplant patients and as therapy for aciclovir-resistant HSV infections." | 2.41 | Prophylaxis against herpesvirus infections in transplant recipients. ( Ljungman, P, 2001) |
| " Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy." | 2.40 | New therapeutic approaches to the alphaherpesvirus infections. ( Cassady, KA; Whitley, RJ, 1997) |
| "Foscarnet treatment has been used with some clinical benefit in patients with acyclovir-resistant HSV or VZV, or ganciclovir-resistant CMV." | 2.39 | Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. ( Reusser, P, 1996) |
| "Agents available to treat herpesvirus infections include idoxuridine, trifluridine, vidarabine and acyclovir for the topical treatment of herpetic eye infections; vidarabine and acyclovir for the systemic (intravenous) treatment of herpes encephalitis; acyclovir for the topical and systemic (oral) treatment of genital herpes; acyclovir for the systemic (intravenous, oral) treatment of HSV or varicella-zoster (VZV) infections in immunosuppressed patients; brivudin for the systemic (oral) treatment of HSV-1 or VZV infections in immunosuppressed patients; and ganciclovir and foscarnet for the systemic (intravenous) treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 2.38 | Antivirals for the treatment of herpesvirus infections. ( De Clercq, E, 1993) |
| "We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application." | 1.43 | Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. ( Ariza-Heredia, EJ; Chemaly, RF; El Chaer, F; El-Haddad, D; Gulbis, AM; Mulanovich, VE; Shah, DP; Shpall, EJ; Vanichanan, J, 2016) |
| " It demonstrated enhanced body weight normalized clearance of cidofovir and cidofovir dosage was augmented to 12 mg/kg per wk to reach adequate drug exposure." | 1.37 | Primary HHV 6 infection after liver transplantation with acute graft rejection and multi-organ failure: successful treatment with a 2.5-fold dose of cidofovir and reduction of immunosuppression. ( Baba, HA; Ballauf, A; Breddemann, A; Dohna-Schwake, C; Fiedler, M; Gerner, P; Gierenz, N; Hoyer, PF; Läer, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.88) | 18.7374 |
| 1990's | 19 (37.25) | 18.2507 |
| 2000's | 15 (29.41) | 29.6817 |
| 2010's | 13 (25.49) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Kotton, BD | 1 |
| Kotton, CN | 1 |
| Zirofsky, D | 1 |
| Rekers, W | 1 |
| Powell, C | 1 |
| Hawley, J | 1 |
| Veir, J | 1 |
| Lappin, M | 1 |
| Coen, N | 1 |
| Duraffour, S | 1 |
| Naesens, L | 3 |
| Krecmerová, M | 1 |
| Van den Oord, J | 1 |
| Snoeck, R | 2 |
| Andrei, G | 2 |
| Piret, J | 1 |
| Boivin, G | 1 |
| Brush, LA | 1 |
| Black, DH | 1 |
| Mccormack, KA | 1 |
| Maxwell, LK | 1 |
| Wright, G | 1 |
| Ritchey, JW | 1 |
| Payton, ME | 1 |
| Eberle, R | 1 |
| Caruso Brown, AE | 1 |
| Cohen, MN | 1 |
| Tong, S | 1 |
| Braverman, RS | 1 |
| Rooney, JF | 1 |
| Giller, R | 1 |
| Levin, MJ | 1 |
| Ledbetter, EC | 2 |
| Spertus, CB | 1 |
| Pennington, MR | 1 |
| Van de Walle, GR | 1 |
| Judd, BE | 1 |
| Mohammed, HO | 1 |
| El-Haddad, D | 1 |
| El Chaer, F | 1 |
| Vanichanan, J | 1 |
| Shah, DP | 1 |
| Ariza-Heredia, EJ | 1 |
| Mulanovich, VE | 1 |
| Gulbis, AM | 1 |
| Shpall, EJ | 1 |
| Chemaly, RF | 1 |
| Marley, MS | 1 |
| Givens, MD | 1 |
| Galik, PK | 1 |
| Riddell, KP | 1 |
| Stringfellow, DA | 1 |
| Tempesta, M | 4 |
| Crescenzo, G | 4 |
| Camero, M | 4 |
| Bellacicco, AL | 4 |
| Tarsitano, E | 3 |
| Decaro, N | 2 |
| Neyts, J | 7 |
| Martella, V | 2 |
| Buonavoglia, C | 4 |
| Dohna-Schwake, C | 1 |
| Fiedler, M | 1 |
| Gierenz, N | 1 |
| Gerner, P | 1 |
| Ballauf, A | 1 |
| Breddemann, A | 1 |
| Läer, S | 1 |
| Baba, HA | 1 |
| Hoyer, PF | 1 |
| Stingaciu, S | 1 |
| Ticchioni, M | 1 |
| Sudaka, I | 1 |
| Haudebourg, J | 1 |
| Mounier, N | 1 |
| Moyo, TK | 1 |
| Richards, KL | 1 |
| Damania, B | 1 |
| Marinaro, M | 1 |
| Armenise, C | 1 |
| Capobianchi, A | 1 |
| Iori, AP | 1 |
| Mauro, FR | 1 |
| Torelli, GF | 1 |
| Micozzi, A | 1 |
| Girmenia, C | 1 |
| Foà, R | 1 |
| Gentile, G | 1 |
| Gervais, KJ | 1 |
| Pirie, CG | 1 |
| Pizzirani, S | 1 |
| Garneau, M | 2 |
| Bolger, GT | 1 |
| Bousquet, C | 2 |
| Kibler, P | 2 |
| Tremblay, F | 1 |
| Cordingley, MG | 1 |
| Tan, HH | 1 |
| Goh, CL | 1 |
| Thiry, J | 2 |
| Thiry, E | 2 |
| Elia, G | 1 |
| Fontenelle, JP | 1 |
| Powell, CC | 1 |
| Veir, JK | 1 |
| Radecki, SV | 1 |
| Lappin, MR | 1 |
| Quenelle, DC | 1 |
| Collins, DJ | 1 |
| Pettway, LR | 1 |
| Hartline, CB | 1 |
| Beadle, JR | 1 |
| Wan, WB | 1 |
| Hostetler, KY | 1 |
| Kern, ER | 2 |
| Smee, DF | 1 |
| Barnett, BB | 1 |
| Sidwell, RW | 1 |
| Reist, EJ | 1 |
| Holy, A | 1 |
| De Clercq, E | 7 |
| Awan, AR | 1 |
| Field, HJ | 2 |
| Balzarini, J | 1 |
| Reusser, P | 1 |
| Robertson, KD | 1 |
| Manns, A | 1 |
| Swinnen, LJ | 1 |
| Zong, JC | 1 |
| Gulley, ML | 1 |
| Ambinder, RF | 1 |
| Cassady, KA | 1 |
| Whitley, RJ | 1 |
| Sadler, R | 1 |
| Raab-Traub, N | 1 |
| Pagano, JS | 1 |
| Takahashi, K | 1 |
| Zabawski, EJ | 1 |
| Cockerell, CJ | 1 |
| Rostkowska-Nadolska, B | 1 |
| Bolger, G | 1 |
| Lapeyre, N | 1 |
| Rhéaume, M | 1 |
| Cordingley, M | 1 |
| Manichanh, C | 1 |
| Grenot, P | 1 |
| Gautheret-Dejean, A | 1 |
| Debré, P | 1 |
| Huraux, JM | 1 |
| Agut, H | 1 |
| Ljungman, P | 1 |
| Lenzo, JC | 1 |
| Shellam, GR | 1 |
| Lawson, CM | 1 |
| Bowers, M | 1 |
| Lalezari, J | 1 |
| Boulanger, E | 1 |
| Agbalika, F | 1 |
| Maarek, O | 1 |
| Daniel, MT | 1 |
| Grollet, L | 1 |
| Molina, JM | 1 |
| Sigaux, F | 1 |
| Oksenhendler, E | 1 |
| Vogel, JU | 1 |
| Michaelis, M | 1 |
| Blaheta, RA | 1 |
| Rabenau, HF | 1 |
| Kreuter, J | 1 |
| Cinatl, J | 1 |
| Doerr, HW | 1 |
| Ho, HT | 2 |
| Woods, KL | 2 |
| Bronson, JJ | 2 |
| De Boeck, H | 1 |
| Martin, JC | 2 |
| Hitchcock, MJ | 2 |
| Gibson, JS | 1 |
| Slater, JD | 1 |
| Ferrara, LM | 1 |
| Ghazzouli, I | 1 |
| Soike, KF | 1 |
| Martin, WB | 1 |
| Hay, D | 1 |
| Crawford, LV | 1 |
| Bouvier, GL | 1 |
| Crawford, EM | 1 |
| Prince, HN | 1 |
| Grunberg, E | 1 |
| Buck, M | 1 |
| Cleeland, R | 1 |
| Borgen, HC | 1 |
| Ludwig, H | 1 |
14 reviews available for cytosine and B Virus Infection
| Article | Year |
|---|---|
Resistant herpes simplex virus infections - who, when, and what's new?
Topics: Acyclovir; Antiviral Agents; Cytosine; Foscarnet; Herpes Simplex; Herpesviridae Infections; Humans; | 2022 |
Antiviral drug resistance in herpesviruses other than cytomegalovirus.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Drug Resistance, Viral; Foscarnet | 2014 |
Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.
Topics: Antiviral Agents; Cidofovir; Cytosine; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Injec | 2010 |
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Ad | 2006 |
Antivirals for the treatment of herpesvirus infections.
Topics: Acyclovir; Antiviral Agents; Belgium; Bromodeoxyuridine; Cidofovir; Cytomegalovirus Infections; Cyto | 1993 |
The potential of acyclic nucleoside phosphonates as broad-spectrum antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Herpesviridae Infections; Humans; Organopho | 1995 |
Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Famcicl | 1996 |
New therapeutic approaches to the alphaherpesvirus infections.
Topics: 2-Aminopurine; Acyclovir; Alphaherpesvirinae; Antibodies, Monoclonal; Arabinofuranosyluracil; Cidofo | 1997 |
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 1998 |
Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.
Topics: Administration, Cutaneous; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; | 1998 |
[Progress in research for new drugs against the herpes virus].
Topics: Acyclovir; Animals; Antiviral Agents; Cytosine; DNA, Viral; Fatty Alcohols; Herpesviridae Infections | 1999 |
Prophylaxis against herpesvirus infections in transplant recipients.
Topics: Antibiotic Prophylaxis; Antiviral Agents; Cidofovir; Cytosine; Foscarnet; Hematopoietic Stem Cell Tr | 2001 |
Recent developments in herpesvirus therapy.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Bromodeoxyuridine; Cidofovir; Cl | 2001 |
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; | 2001 |
2 trials available for cytosine and B Virus Infection
| Article | Year |
|---|---|
Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients.
Topics: Acute Kidney Injury; Adenovirus Infections, Human; Adolescent; Antiviral Agents; BK Virus; Child; Ch | 2015 |
Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats.
Topics: Administration, Topical; Animals; Antiviral Agents; Cat Diseases; Cats; Cidofovir; Conjunctivitis, V | 2008 |
35 other studies available for cytosine and B Virus Infection
| Article | Year |
|---|---|
Feline Herpesvirus 1 and Mycoplasma spp. Conventional PCR Assay Results From Conjunctival Samples From Cats in Shelters With Suspected Acute Ocular Infections.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Antiviral Agents; Cat Diseases; Cats; Cidofovir; Conj | 2018 |
Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.
Topics: Animals; Antiviral Agents; Apoptosis; Blotting, Western; Cells, Cultured; Cidofovir; Cyclic AMP; Cyt | 2013 |
Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus).
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Animal; Gancic | 2014 |
In Vitro and In Vivo Evaluation of Cidofovir as a Topical Ophthalmic Antiviral for Ocular Canine Herpesvirus-1 Infections in Dogs.
Topics: Administration, Ophthalmic; Animals; Antiviral Agents; Chlorocebus aethiops; Cidofovir; Cytosine; Di | 2015 |
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
Topics: Aged; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2016 |
Lactoferrin from bovine milk inhibits bovine herpesvirus 1 in cell culture but suppresses development of in vitro-produced bovine embryos.
Topics: Animals; Antiviral Agents; Cattle; Cells, Cultured; Cidofovir; Cytosine; Dose-Response Relationship, | 2009 |
Assessing the efficacy of cidofovir against herpesvirus-induced genital lesions in goats using different therapeutic regimens.
Topics: Animals; Antiviral Agents; Base Sequence; Cidofovir; Cytosine; Disease Models, Animal; DNA Primers; | 2008 |
Primary HHV 6 infection after liver transplantation with acute graft rejection and multi-organ failure: successful treatment with a 2.5-fold dose of cidofovir and reduction of immunosuppression.
Topics: Antiviral Agents; Child, Preschool; Cholestasis, Intrahepatic; Cidofovir; Cytosine; Female; Graft Re | 2011 |
Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cidofovir; Cyclophosphamide; | 2010 |
Cidofovir does not prevent caprine herpesvirus type-1 neural latency in goats.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA, Viral; Female; Ganglia; | 2010 |
Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient.
Topics: Antibodies, Viral; Cidofovir; Cytosine; DNA, Viral; Encephalitis; Fatal Outcome; Foscarnet; Ganciclo | 2011 |
Acute primary canine herpesvirus-1 dendritic ulcerative keratitis in an adult dog.
Topics: Animals; Antiviral Agents; Cidofovir; Corneal Ulcer; Cytosine; Dog Diseases; Dogs; Herpesviridae Inf | 2012 |
HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Disease Models, Animal; E | 2003 |
Cidofovir is effective against caprine herpesvirus 1 infection in goats.
Topics: Animals; Cidofovir; Cytosine; Disease Models, Animal; Goats; Herpesviridae Infections; Organophospho | 2007 |
Potent inhibition of genital herpesvirus infection in goats by cidofovir.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Goats; Herpes Genitalis; Herpesviridae Infections; O | 2007 |
Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegaloviru | 2008 |
Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus.
Topics: Acyclovir; Animals; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Foscarnet; Ga | 1995 |
New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine | 1994 |
Effects of phosphonylmethoxyalkyl derivatives studied with a murine model for abortion induced by equine herpesvirus 1.
Topics: Abortion, Spontaneous; Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Female; Herpesvirida | 1993 |
CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Topics: 5-Methylcytosine; Anemia, Aplastic; Burkitt Lymphoma; CpG Islands; Cytosine; DNA (Cytosine-5-)-Methy | 1996 |
In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Chlorocebus aethiops; Cidofovir; Cytosine; | 1998 |
The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice.
Topics: Adolescent; Animals; Antiviral Agents; Apoptosis; Carcinoma; Cidofovir; Cytosine; Drug Screening Ass | 1998 |
Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis.
Topics: Alanine Transaminase; Animals; Antiviral Agents; Aspartate Aminotransferases; Body Weight; Cidofovir | 1999 |
Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis.
Topics: Antibodies, Monoclonal; Antigens, Surface; Antigens, Viral; Antiviral Agents; Cidofovir; Cytosine; D | 2000 |
Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Ganciclovir; Herpesviridae I | 2001 |
Herpesviruses.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Cidofovir; Complementary Therapi | 1995 |
Drug-resistant herpes: cidofovir gel in limbo. Interview with Jay Lalezari, M.D. Interview by John S. James.
Topics: Administration, Topical; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytosine; Drug Appro | 1997 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Administration, Topical; Amantadine; Animals; Antivi | 2002 |
Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo.
Topics: Adjuvants, Immunologic; Animals; Antiviral Agents; Cell Adhesion; Cell Line; Chelating Agents; Cidof | 2002 |
Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Topics: Animals; Antiviral Agents; Carbon Radioisotopes; Cells, Cultured; Cidofovir; Cytosine; Herpesviridae | 1992 |
The activity of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Brain Diseases; Cidofovir; Cytosine; Drug Adm | 1992 |
(S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cidofovir; Cytomegalovirus Infections; C | 1990 |
Characteristics of bovine mammillitis virus.
Topics: Animals; Cattle; Cattle Diseases; Centrifugation, Density Gradient; Chloroform; Culture Techniques; | 1966 |
A comparative study of the antitumor and antiviral activity of 1-beta-D-arabinofuranosyl-5-fluorocytosine (FCA) and 1-beta-D-arabinofuranosylcytosine (CA).
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Ehrlich Tumor; Culture Techniques; | 1969 |
Equine herpesvirus 1: biological and biophysical comparison of two viruses from different clinical entities.
Topics: Abortion, Veterinary; Animals; Antigens, Viral; Base Sequence; Cell Line; Centrifugation, Density Gr | 1974 |